Chronic hepatitis C virus (HCV) infection affects 40,000 HIV positive patients in the United States. HCV treatment is associated with life-threatening side effects and antiretroviral drug interactions. Without treatment, increasing numbers of HIV positive patients will either die from end stage liver disease or from HIV-related complications because of the inability to use antiretroviral agents due to their hepatotoxicity. Data are limited, but the clinical impression is that this population less often accepts or completes HCV treatment. More information is needed about the experience of HIV-infected patients as they manage the process of HCV treatment. The purpose of this qualitative, longitudinal study is to develop a clear understanding of HIV-infected patients' experiences with HCV treatment. This understanding will improve our ability to design clinical interventions that support HCV treatment efforts in co-infected patients.
The specific aims of this study are to (1) describe the subjective experiences of HIV-infected patients as they manage the process of HCV treatment, (2) examine the influence of health related quality of life, symptom experience, mental illness, substance abuse and the role of health care providers on the experience of HCV treatment in co-infected patients, and (3) explore the association between demographic, clinical cofactors and the HCV treatment experience. In-depth qualitative interviews will be conducted with 40 HCV/HIV co-infected patients at three time points (before treatment, 8-12 weeks into treatment and at treatment completion). Subjects who choose not to be treated will be interviewed also. The constant comparative method of content analysis will be used to abstract interview data on the HCV treatment experience. A meta-matrix will be used to integrate the qualitative, demographic and clinical cofactor data (HCV treatment adherence, HIV RNA, HCV RNA, HCV genotype, liver pathology, complete blood counts, liver function tests, HIV illness stage and co-treatment with antiretroviral agents). The proposed study is an essential step towards developing the foundation for clinical trials that test HCV treatment interventions among HIV-infected patients. Results of this study will also be valuable to clinicians, educators, researchers and those who develop treatment guidelines for HCV/HIV co-infected patients. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Nursing Research (NINR)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15NR008341-01
Application #
6590149
Study Section
Special Emphasis Panel (ZRG1-AARR-8 (01))
Program Officer
Hare, Martha L
Project Start
2003-01-01
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2004-12-31
Support Year
1
Fiscal Year
2003
Total Cost
$159,000
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Nursing
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Bova, Carol; Ogawa, Lisa Fink; Sullivan-Bolyai, Susan (2010) Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care 21:63-74
Ogawa, Lisa M Fink; Bova, Carol (2009) HCV treatment decision-making substance use experiences and hepatitis C treatment decision-making among HIV/HCV Coinfected Adults. Subst Use Misuse 44:915-33
Bova, Carol; Jaffarian, Carol; Himlan, Pauline et al. (2008) The Symptom Experience of HIV/HCV-Coinfected Adults. J Assoc Nurses AIDS Care 19:170-80
Sullivan-Bolyai, Susan; Bova, Carol; Deatrick, Janet A et al. (2007) Barriers and strategies for recruiting study participants in clinical settings. West J Nurs Res 29:486-500
Sullivan-Bolyai, Susan; Bova, Carol; Harper, Doreen (2005) Developing and refining interventions in persons with health disparities: the use of qualitative description. Nurs Outlook 53:127-33